Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163085 | 0.99 | TK2 (0.43) | TK2TK1 | |
| SCHEMBL4725276 | 0.91 | TK1 (0.38) | TK2TK1 | |
| SCHEMBL4728681 | 0.90 | TK1 (0.39) | TK1 | |
| SCHEMBL887851 | 0.87 | TK1 (0.43) | TK1 | |
| SCHEMBL9113442 | 0.87 | TK1 (0.38) | TK2TK1 | |
| SCHEMBL4727501 | 0.86 | TK1 (0.41) | TK1 | |
| SCHEMBL14388593 | 0.86 | TK1 (0.43) | TK1 | |
| SCHEMBL27436150 | 0.86 | TK1 (0.43) | TK1 | |
| SCHEMBL28250600 | 0.85 | TK1 (0.39) | TK2TK1 | |
| SCHEMBL1517629 | 0.85 | TK1 (0.44) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559516-B2 | Multi-fluorous blockmer for oligonucleotide synthesis, and oligonucleotide synthesis method using the same | Natias Inc. (JP) | 2026-02-24 | — | — | US | disclosed |
| EP-3960749-B1 | MULTI-FLUOROUS BLOCKMER USED IN OLIGONUCLEOTIDE SYNTHESIS AND OLIGONUCLEOTIDE SYNTHESIS METHOD USING SAME | NATIAS INC (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-20220235089-A1 | Multi-Fluorous Blockmer for Oligonucleotide Synthesis, and Oligonucleotide Synthesis Method Using the Same | Natias Inc. (JP) | 2022-07-28 | — | — | US | disclosed |
| EP-3960749-A1 | MULTI-FLUOROUS BLOCKMER USED IN OLIGONUCLEOTIDE SYNTHESIS AND OLIGONUCLEOTIDE SYNTHESIS METHOD USING SAME | Natias Inc. (JP) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559516-B2 | Multi-fluorous blockmer for oligonucleotide synthesis, and oligonucleotide synthesis method using the same | NSUN2, FBL, RNGTT | TK2 533/4885TK1 179/4885 |
| US-20220235089-A1 | Multi-Fluorous Blockmer for Oligonucleotide Synthesis, and Oligonucleotide Synthesis Method Using the Same | NSUN2, FBL, RNGTT | TK2 582/4885TK1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.